Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals Q4 2023 Earnings Report

ARS Pharmaceuticals logo
$10.31 +0.03 (+0.29%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$10.54 +0.23 (+2.24%)
As of 10/3/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

ARS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARS Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

ARS Pharmaceuticals' Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

ARS Pharmaceuticals Earnings Headlines

What is William Blair's Forecast for SPRY FY2025 Earnings?
Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
See More ARS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

View ARS Pharmaceuticals Profile

More Earnings Resources from MarketBeat